EPIX Stock Overview
A clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
ESSA Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.52 |
52 Week High | US$11.67 |
52 Week Low | US$2.58 |
Beta | 1.83 |
11 Month Change | 2.79% |
3 Month Change | -21.92% |
1 Year Change | 99.28% |
33 Year Change | -79.16% |
5 Year Change | 100.91% |
Change since IPO | -93.75% |
Recent News & Updates
Recent updates
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate
Feb 18ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans
Aug 16Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)
Jan 25We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely
Dec 15ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen
Feb 02ESSA Pharma and Janssen to test combo treatments in prostate cancer setting
Jan 13ESSA Pharma EPS beats by $0.02
Dec 15Shareholder Returns
EPIX | US Biotechs | US Market | |
---|---|---|---|
7D | 11.1% | 5.0% | 2.2% |
1Y | 99.3% | 15.2% | 22.6% |
Return vs Industry: EPIX exceeded the US Biotechs industry which returned 13.6% over the past year.
Return vs Market: EPIX exceeded the US Market which returned 22% over the past year.
Price Volatility
EPIX volatility | |
---|---|
EPIX Average Weekly Movement | 10.4% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: EPIX's share price has been volatile over the past 3 months.
Volatility Over Time: EPIX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 50 | David Parkinson | www.essapharma.com |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc. Fundamentals Summary
EPIX fundamental statistics | |
---|---|
Market cap | US$248.88m |
Earnings (TTM) | -US$27.73m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.8x
P/E RatioIs EPIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EPIX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$27.73m |
Earnings | -US$27.73m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.63 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did EPIX perform over the long term?
See historical performance and comparison